Thanks. At risk of diverting too far off topic, not necessarily bad for ABBV744 either, because:

In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514. Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. 

Maybe some competition for Zenith on that score?  

Anyway, they weren't the only example by a long shot.

It seems so important that this BET inhibition avenue be explored and developed that i can't even be entirely bummed when stiff competition looms.

Even so i wish we could move a bit faster. 

Clinical studies may be slowed down during the pandemic, but clearly cardiovascular issues are not. Given the adverse effects of covid on the heart, maybe that is justification to reprioritize cardiovascular studies as well as covid and cancer studies.

We need to get the BETonMACE trial moving again, even if it means taking the slower route with greater population, etc.